Passive Diffusion vs Active pH-Dependent Encapsulation of Tyrosine Kinase Inhibitors Vandetanib and Lenvatinib into Folate-Targeted Ferritin Delivery System
Zuzana Skubalova,1,2 Simona Rex,1,2 Martina Sukupova,1 Martin Zahalka,1 Petr Skladal,3 Jan Pribyl,3 Hana Michalkova,1,2 Akila Weerasekera,4 Vojtech Adam,1,2 Zbynek Heger1,2 1Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech Republic; 2Central European Institute of Tech...
Guardado en:
Autores principales: | Skubalova Z, Rex S, Sukupova M, Zahalka M, Skladal P, Pribyl J, Michalkova H, Weerasekera A, Adam V, Heger Z |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9696b6f0dd2846acb00866412d6aad4f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Bisdemethoxycurcumin alleviates vandetanib-induced cutaneous toxicity in vivo and in vitro through autophagy activation
por: Ying Jin, et al.
Publicado: (2021) -
The impact of individual human cytochrome P450 enzymes on oxidative metabolism of anticancer drug lenvatinib
por: Katarína Vavrová, et al.
Publicado: (2022) -
Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
por: Tetsu Tomonari, et al.
Publicado: (2021) -
Pneumatosis intestinalis associated with lenvatinib during thyroid cancer treatment: a case report
por: Soji Toda, et al.
Publicado: (2021) -
Treatment of metastatic hepatocellular carcinoma with lenvatinib. Case report and literature review
por: Konstantin V. Menshikov, et al.
Publicado: (2021)